Teva Pharma`s Generics Tiopronin Receives Approval in US
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
A little more than a year after Hikma Pharmaceuticals accused Amarin of “deliberately and meticulously” hamstringing supplies of the main ingredient in its only marketed drug, Vascepa, to thwart potential generic competition, Teva Pharmaceuticals has levied a similar challenge.
Teva reports revenue increase, says it will sell API business
Israeli pharmaceutical giant Teva has announced the launch of the first available generic version of a nasal spray used to treat opioid overdose.
Teva`s Ajovy can`t find solid win against oral migraine rivals
Health Canada Issues Recall of Teva`s Losartan
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a post hoc analysis of a long-term, 3-year open-label extension (OLE) study examining efficacy and safety endpoints for the use of AUSTEDO (deutetrabenazine) tablets in younger (<55 years) and older (?55 years) patients with tardive dyskinesia (TD). The findings, published online in The American Journal of Geriatric Psychiatry, evaluated the long-term use of AUSTEDO with the total motor Abnormal Involuntary Movements Scale (AIMS) score, and measures of treatment success and quality of life.
One of the gems AbbVie inherited from the $63 billion Allergan transaction is ready to take a slice of the highly competitive migraine market—and no, it’s not Botox.
Teva Wins Appeal That Upholds Three Patents for Migraine Drug